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Abstract
Background: The aim of the study was to evaluate the composition and the temporal evolution of the oropharyngeal
microbiome in antibiotic-naïve patients requiring mechanical ventilation and to gain new insights into the pathogenesis
of ventilator-associated pneumonia (VAP).
Methods: Prospective, observational single-center nested case-control study. Patients with acute critical illness
and anticipated duration of mechanical ventilation > 4 days were eligible. We took oropharyngeal swabs (and if
available, tracheal secretions) daily, starting at the day of intubation. The microbiota was characterized by 16S
rRNA high-throughput sequencing and compared between patients developing VAP versus controls.
Results: Five patients developed VAP. In three patient the causative pathogens were Enterobacteriaceae and in
two Haemophilus influenzae. Locally weighted polynomial regression suggested that the within diversity (=alpha) was
lower in Enterobacteriaceae VAP patients between days two to five of mechanical ventilation when compared to
controls. Detection of Enterobacteriaceae in the oropharynx occurred on day two of follow-up and consisted of a
single operational taxonomic unit in 2/3 patients with enterobacterial VAP.
Conclusions: In acutely-ill patients who developed enterobacterial VAP the causative pathogen gained access to the
oropharynx early after starting mechanical ventilation and outgrew the commensal members of the microbiome.
Whether a specific pattern of the oropharyngeal microbiome between days three to five of mechanical ventilation may
predict VAP enterobacterial VAP has to be evaluated in further studies.
Keywords: Ventilator-associated pneumonia, Intensive care, Oropharyngeal and tracheal microbiome, Infection prevention,
Nosocomial pneumonia
Background
Ventilator-associated pneumonia (VAP) is the most
common hospital-acquired infection in intensive care
units (ICU), and is associated with prolonged mechanical
ventilation, increased mortality, higher costs, and in-
creased antibiotic consumption [1–4]. Microaspiration of
the oropharyngeal microbiota represents an important
pathway leading to VAP [4, 5]. Most measures to decrease
VAP rates aim at preventing the transfer of pathogens
from the oropharynx to the lungs [6]. A meta-analysis
showed that oral decontamination was the only interven-
tion to reduce mortality in the context of VAP [7]. Reliable
markers to predict the onset of VAP do not exist. Con-
tinuous surveillance cultures may predict the microbial
cause of a VAP for Streptococcus pneumoniae, Acinetobac-
ter spp., and/or other multi-drug resistant Gram-negative
bacteria [8, 9] and therefore help with the selection of ap-
propriate antibiotic therapy. However, surveillance cul-
tures do not predict the time of onset of VAP, nor provide
essential information for preventive measures [9].
The human microbiome is defined as the ecological
community of commensal, symbiotic and pathogenic
microorganisms that inhibit body spaces [10]. The
human lung microbiome and its role in health and disease
has gained greater attention among researchers in the last
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10 years [11–13]. The lower respiratory tract has historically
been considered sterile, but recent evidence supports the
concept that a distinct microbiota of the lower respiratory
tract is present both in health and in various respiratory
diseases [14–16]. Some authors argue that the pharyngeal
microbiome may have a protective role in respiratory tract
infections and that artificial reinforcement of microbiome
homeostasis would be an option to prevent invasion of
species causing infections [17]. In contrast, during in-
fluenza infection, the respiratory microbiome seems to
undergo only very discrete changes [18].
The use of longitudinal study designs is essential to
gain an understanding of the variation of the microbiome
within individual subjects and during development of
VAP [19]. A common approach for assessing community
changes is the evaluation of the within-subject changes in
bacterial diversity (=alpha; the variety and abundance of
organisms in the microbiome) over time. However, it is
also essential to use an in-between diversity measure
(=beta; the dissimilarity between multiple microbiomes/
samples) that captures changes in microbiome compos-
ition rather than just diversity [19].
More recently, the sputum microbiome was found to
be indicative of clinical outcomes in lung diseases such
as cystic fibrosis and COPD [20–22].
Previous longitudinal analyses of respiratory tract
microbiota have provided some insight into the patho-
genesis of VAP in critically ill patients [23, 24]. 16S
rRNA gene sequencing of endotracheal aspirate samples
allowed a broader look of bacterial communities [24].
Dysbiosis of microbial communities in the respiratory
tract was most pronounced in patients who already had
developed VAP [23]. However, no longitudinal study has
yet been performed in acutely ill patients using daily
oropharyngeal swabs with paired tracheal secretions.
Our goal was to describe the longitudinal dynamics of
the oropharyngeal and tracheal microbiota and stratify
this evolution for the onset or absence of a VAP. Our
main study hypotheses were i) VAP is associated with
disturbed oropharyngeal microbiota, ii) distinct oper-
ational taxonomic units of the Enterobacteriaceae family
have a specific dynamic pattern of gaining access to the
oropharynx during the course of mechanical ventilation
and iii) the causative Enterobacteriaceae may outgrow
the commensal members of the microbiome.
Methods
Study design and setting
The study was designed as a prospective, single-center
nested case-control study and was performed at the
Department of Intensive Care Medicine (ICU) at Bern
University Hospital, Switzerland. The ICU is a 60-bed
unit admitting > 6500 patients per year and is the sole
provider of intensive care for adults at the hospital,
handling medical, surgical and trauma patients. More
than 3500 patients per year require mechanical ventila-
tion. Subjects were screened for inclusion between
December 2015 and November 2016. The study was
conducted in compliance with the study protocol, the
current version of the Declaration of Helsinki, the Inter-
national Council for Harmonisation-Good Clinical Practice
as well as all national legal and regulatory requirements.
Participants
Consecutive patients admitted to the ICU due to cranio--
cerebral trauma, stroke or subarachnoid hemorrhage, and
patients with cardiogenic shock were assessed for study in-
clusion, as prior antibiotic treatment tends to be rare in
these patients. Patients were screened by the study team
within 24 h after oral intubation for eligibility. Inclusion
criteria were: age between 18 and 80 years, and antici-
pated duration of mechanical ventilation longer than
48 h as determined by the intensivist in charge (with
the aim of identifying as many patients as possible who
will eventually be ventilated for at least 4 days). Predefined
exclusion criteria were chronic immunosuppressive ther-
apy or comorbidities associated with immunosuppression
(neutropenia < 0.5 G/l; active leukemia or lymphoma; HIV
with CD4 < 200 cells/μl; splenectomy patients; < 4 weeks
post-transplant; cytotoxic chemotherapy; high-dose
steroids > 2 weeks with prednisone equivalent > 20 mg/
d or > 1 week with > 40mg/die); systemic antibiotic the-
rapy in the last 3months (except perioperative prophy-
laxis); active infection upon study screening that required
immediate or deferred (within 48 h) systemic antibiotic
therapy.
Eligible patients were unable to give consent for the
study at the time of enrollment because of mental incap-
acity due to the underlying medical condition and mechan-
ical ventilation. Before a patient was enrolled, a physician
who was not participating in the study confirmed that the
interests of the patient were safeguarded and that all inclu-
sion criteria and no exclusion criteria were present. Inclu-
sion occurred after requesting study consent from a patient
representative. Patient’s informed consent was sought in a
later phase, as soon as the patient’s condition had improved
sufficiently. We aimed at including 30 patients to accrue 5–
8 VAP cases, as the predicted rate was between 20 and
30%. Overall, ten subjects were included for further pro-
cessing of the samples (i.e., microbiome evaluation). This
included the VAP cases and control patients ventilated for
more than four days.
Clinical variables
The intensivists prospectively collected variables for
study patients. These included: Age, gender, SAPS II
score upon ICU admission, date of ICU admission, previ-
ous and new antibiotic treatment (start and stop date, class,
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cumulative dose), duration of mechanical ventilation,
tracheotomy, duration of ICU stay, degree of respiratory
failure at beginning and end of mechanical intubation
(PaO2/FiO2), and predominant parameter settings of the
mechanical ventilation. All parameters were transferred
into a spreadsheet by the ICU’s study nurse team at the
end of each study day.
Outcomes
Clinical VAP was defined as a patient with a new or
progressive pulmonary infiltrate on chest radiography
(according to the radiology report). Also, two of the fol-
lowing three criteria were required: body temperature
higher than 38 °C, leukocyte count greater than 12 G/L
or lower than 4G/L, and/or purulent respiratory secretions
within 48-h before/after the radiography. A confirmed VAP
required additional detection of a causative pathogen –
either by microbiological culture or via microbiome analysis
from a tracheal sample. VAP cases were then subgrouped
in enterobacterial vs. Haemophilus influenzae. For the
control group, patients with ‘no VAP’ were chosen. We
addressed the potential bias of misclassifying cases into
VAP and controls by having the diagnostic criteria validated
by an independent study nurse. This study nurse was
blinded in terms of medical records and medications.
Microbiome
Sampling: For uniformity reasons, all samples were col-
lected by a study nurse. Oropharyngeal samples were
taken using eswabs™ (Copan; Murrieta, CA, USA) and
immediately stored at − 80 °C. Initial sampling was per-
formed immediately after inclusion; daily follow-up sam-
ples were taken each morning before oral hygiene (teeth
brushing followed by oral decontamination with chlor-
hexidine 0.2%). A final sample was taken together at the
time of VAP diagnosis or before extubation. If available,
tracheobronchial samples were simultaneously collected
in a 50ml tube and stored at − 80 °C. Additionally, the
VAP diagnosis sample was sent for routine microbio-
logical assessment.
Processing: Sample processing was performed as re-
cently described [25]. A detailed description is provided
in the Additional file 1. The sequence reads were sub-
mitted to the European Nucleotide Archive (accession
number: PRJEB26875).
Fig. 1 Flowchart. The process of subject screening, inclusion, and selection for microbiome evaluation is shown in the flow chart. Subjects were
selected to fulfill possible VAP criteria according to clinical criteria (new infiltrate plus two of the following three: temperature greater than 38 °C,
leukocyte count greater than 12 G/L or lower than 4 G/L, or purulent respiratory secretions)
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Statistics
Cases characteristics were summarized in a table. Base-
line characteristics were compared with chi-square and
Mann-Whitney-U tests, as appropriate.
The sample’s microbiome within-subject diversity
(=alpha) was determined using the richness and Shannon
diversity indices (vegan package; diversity function in R
[26]). Summary alpha diversities were plotted by applying
Fig. 2 Timeline. For each study patient who underwent microbiome evaluation, a timeline indicates the moment of intubation, study start,
endpoint (VAP or extubation), and if performed tracheostomy. Intermittent extubations and reintubations < 24 h were not exclusion criteria and
are highlighted in the timeline in parentheses. Each study day lasted from noon to noon of the following day. Follow up sampling was taken at
8 am each day, indicated by dotted, vertical lines, usually starting on day 1. If a paired tracheobronchial secretion was taken in addition to the
oropharyngeal sample, times were indicated (+T). In order to align follow-up samples of all study subjects: If the study begin on day 1 was after
8 am, the first follow-up sample was only taken on day 2 (i.e., for subjects 01, 17, 25)
Sommerstein et al. Antimicrobial Resistance and Infection Control            (2019) 8:81 Page 4 of 10
a LOESS smoother on the increasing sample days [26].
Due to the overall small sample size, the alpha diversity of
cases with Enterobacteriaceae VAP was visually compared
to H. influenzae VAPs and to all subjects without VAP
and no statistical test was applied.
The between sample dissimilarity (=beta diversity) was
calculated using the vegdist function in R [26]. Differ-
ences were evaluated by applying T-tests. P-values < 0.05
were considered significant. All graphs were generated
in R [26].
Results
Study patients
During the study period, 829 ICU admissions were
screened for inclusion (Fig. 1). A total of 30 (3.6%) sub-
jects fulfilled inclusion criteria and 10/30 (1.2% of all)
nested patients were selected for microbiome evaluation
according to the pre-defined criteria. The main reasons
for not evaluating the microbiome were early extubation
within three days and/or early therapy withdrawal. Of
the ten patients, five had a confirmed VAP between days
5–7 after inclusion (Fig. 2). Of these five VAP patients, a
microbiological diagnosis was obtained by conventional
culture methods in four subjects – and by microbiome
analysis in one subject (Proteus vulgaris being the causa-
tive operational taxonomic unit). The causative patho-
gens were Enterobacteriaceae in three subjects and H.
influenzae in two subjects (Table 1).
Baseline characteristics of the subjects are listed in
Table 1. Baseline characteristics did not significantly dif-
fer between VAP cases and controls for gender (p =
0.49), diagnosis (p = 0.34), and days of enrollment (p =
0.42). Patients with VAP were older (median 78, IQR
71–79) than controls (45, 41–69; p = 0.03). Also, SAPS
scores were higher in VAP (79, 77–82) than controls
(50, 47–50; p = 0.02), and so were APACHE IV scores
(27.5, 26.5–28.5 vs. 22, 20–25; p = 0.03).
Figure 2 shows a timeline of each study patient that
underwent microbiome evaluation, reporting critical
events related to mechanical ventilation, study onset and
termination, the sampling strategy and administration of
prophylactic antibiotics. Of note, eight of the ten pa-
tients received prophylactic antibiotics during intubation
because they underwent surgical procedures.
Sequence analysis, taxonomic assignments and
dissimilarity values of oropharyngeal swabs and TBS
In total, 71 oropharyngeal swabs were collected from
five VAP patients and five controls, respectively. Add-
itionally, 51 paired and one non-paired TBS were in-
cluded. For all samples (n = 123), we performed
subsequent 16S rRNA gene sequencing and received a
total of 12,134,989 good quality sequence reads (mean
98,658; 95% CI 83,106-114,211).
Overall, dada2 analyses of sequence reads revealed a
total of 1688 variants which grouped into 155 bacterial
families. As for the latter, the relative abundances of the
most abundant families (less abundant families were
grouped as ‘others’) are visualized in two heatmaps for
each sample (Fig. 3). Prevotellaceae, Veillonellaceae and
Streptococcaceae were most frequently identified.
We then created an abundance-based distance matrix
and received dissimilarity values for each time point for
which two samples were available (right column; Fig. 3).
Dissimilarity values of samples from the lower as com-
pared to the upper airways (oropharyngeal swabs) were
generally large and there was no clear correlation if VAP
patients were compared with controls. This is not true
for patient No. 3 for which a decrease in dissimilarity
was revealed.
Table 1 Subject characteristics and pneumonia diagnosis
Subject Sex Age Main Diagnosis SAPS Score
24h after
ICU admission
APACHE IV
Score 24h after
ICU admission
Days
enrolled
Sample
method
Pathogens detected Confirmed
VAP
1 m 79 Cardiac arrest 82 30 5 TBS Haemophilus influenzae Y
3 f 56 Subarachnoidal hemorrhage 56 28 7 TBS Klebsiella oxytoca Y
7 m 69 Polytrauma with intracranial
hemorrhage
39 11 10 NA NA N
8 m 70 Cardiac arrest 72 26 5 NA NA N
16 m 78 Cardiac arrest 77 ND 5 TBS Morganella morganii Y
17 m 80 Subarachnoidal hemorrhage 79 25 5 TBS Haemophilus influenzae Y
20 m 71 Intracranial hemorrhage 91 27 7 TBS Proteus vulgarisa Y
25 f 41 Subarachnoidal hemorrhage 47 22 5 NA NA N
26 f 45 Subarachnoidal hemorrhage 50 20 8 NA NA N
27 m 22 Polytrauma with intracranial
hemorrhage
50 25 9 TBS Not detected N
a Proteus vulgaris identified via microbiome analysis
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Access of Enterobacteriaceae to the oropharynx and
occurrence of VAP
We detected Enterobacteriaceae in the oropharynx on
at least one day during the first five days of mechan-
ical ventilation above 2% (relative abundance) in 40%
(4/10) of patients (Fig. 4). Three of these four
patients were later diagnosed with an enterobacterial
VAP.
In two of these three patients a single enterobacterial
operational taxonomic unit was found. The detection of
Enterobacteriaceae in the oropharynx correlated with
the subsequent colonization of the tracheobronchial
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Fig. 3 Heatmap of oropharyngeal and tracheobronchial samples. Relative abundances of bacterial communities of the subjects are shown. The left
main column are oropharyngeal samples, the middle tracheobronchial and the right shows the relative dissimilarity between the two corresponding
samples. Each subcolumn for oropharyngeal (oro) and tracheobronchial (tbs) samples represents family-level taxonomic assignment of the sample’s
16S rRNA gene sequences. The color indicates proportional abundance of the sequences assigned to each bacterial family within the sample. The
rows represent individual time points of sampling for the subjects. IO and IT represent the initial oropharyngeal and tracheobronchial samples,
respectively. Missing samples are indicated with grey fill
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system, both in terms of time and operational taxonomic
units (Fig. 4).
Alpha diversity measurements within oropharyngeal samples
Next, we examined if longitudinal alpha diversity mea-
surements within the oropharynx differed in patients with
enterobacterial VAP from other patients. The "richness"
values appeared lower in Enterobacteriaceae VAP patients
but not in H. influenzae VAP when compared to controls
(Fig. 5a). Similarly, the Shannon diversity indices (SDI) for
Enterobacteriaceae VAP patients appeared lower than for
H. influenzae and controls (Fig. 5b).
Beta diversity measurements in-between oropharyngeal
samples
When comparing the oropharyngeal microbiomes in in-
dividual patients between the initial sample and day 4,
the dissimilarity was not significantly different among
patients with Enterobacteriaceae VAP, H. influenzae VAP
or controls (Additional file 1: Figure S1).
Discussion
We described the longitudinal dynamics of the oropha-
ryngeal and tracheal microbiota in a highly selected co-
hort of previously antibiotic-naïve mechanically
ventilated patients. Our study identified two important
points: firstly, patients with enterobacterial VAP appear
to develop a lower within (=alpha) diversity of the oro-
pharyngeal microbiota compared to non-VAP/H. influ-
enzae VAP patients. A lowered SDI/richness could
therefore be indicative of subsequent VAP occurrence
caused by Enterobacteriaceae. Secondly, we showed that
VAP causative Enterobacteriaceae accessed the orophar-
ynx early during ventilation (day 2), with a small initial
abundance. Of interest, this enterobacterial ‘access’ con-
sisted of a single operational taxonomic unit in 2/3 pa-
tients, where the causative bacteria outgrew the residual
microbiota and led to VAP. This points to the access
of a single clone. These two observations can be used
to investigate in a follow-up study with less stringent
inclusion criteria whether a defined longitudinal oro-
pharyngeal microbiome pattern between day zero and
two of mechanical ventilation may predict VAP.
There are several significant limitations to this study.
The most important is the small study size – with only 5
VAP and 5 control patients given the restrictive inclu-
sion criteria.
Of note, the low number of patients led to the
post-hoc formation of somehow arbitrary VAP sub-
groups (enterobacterial versus H. influenzae). On the
other hand, these criteria allowed us to focus on patients
with a relatively undisturbed initial microbiome – as
Fig. 4 Early access of VAP causative Enterobacteriaceae to the oropharynx. Relative abundance of causative (red) and any other (green)
Enterobacteriaceae operational taxonomic units is shown for ten individual study subjects. Results of paired oropharyngeal (upper panels) and
tracheobronchial (lower panels) samples are shown. Enterobacteriaceae VAP patients are subjects 3, 16 & 20. The x-axis denotes days post intubation
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they had been antibiotic-free for the last three months
and were not receiving antibiotic treatment for any
active infection.
During two years in our academic hospital, we
screened every admission to the ICU with conventional
prolonged mechanical ventilation for possible inclusion.
It must therefore with emphasized that it was not a
small study, but a very selective one.
Next, we did not obtain tracheobronchial secretion
samples at each time point. Daily induction of sputum
was considered unethical in this critically ill cohort and
therefore omitted. As a consequence, not all oropharyn-
geal samples can be compared with their tracheobron-
chial counterparts and the value of the tracheobronchial
longitudinal evaluation was therefore hampered. Next,
VAP diagnosis was mainly based on clinical/radiological
criteria and did not take the ventilator settings into
account. This may have led to a bias in the assignment
of cases and controls. Finally, absence of daily chest
x-rays could be a reason for further imprecision in the
diagnosis of VAP.
Priority was given to the continuous morning sam-
pling before chlorhexidine disinfection for all the
follow-up samples every 24 h. This may have influenced
the comparability of the dynamic microbiome evolution
since repeated morning sampling was not done in rela-
tion to the time of intubation. Another limitation was
the frequent use of antibiotic prophylaxis during the
study, which could have had an impact on the compos-
ition and the dynamic of the microbiome. Previously it
was shown, that long-term macrolide treatment chan-
ged the composition of respiratory microbiota and was
associated with decreased bacterial richness [27–29]. In
a previous VAP study though, it was shown that
Fig. 5 Decrease of oropharyngeal longitudinal alpha diversity in enterobacterial VAP. Longitudinal changes in alpha diversity of the
oropharyngeal samples of the individual patients (dots) and by VAP diagnosis. Lines are based on a local polynomial regression fitting (loess
function in R, grey bands indicate 95% CI). a Richness, b Shannon diversity index. Note: Summary lines for H. influenzae VAP patients were
omitted due to low number of cases (n = 2)
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systemic antibiotic administration were not associated
with changes in the alpha diversity [23]. Therefore it is
difficult to estimate how much these antibiotics con-
founded the results.
We interpret our results as important new insight
into the pathogenesis of VAP. It was surprising to see
that a single causative operational taxonomic unit ac-
cesses the oropharynx early on and then outgrows
commensal members. This finding may have import-
ant implications for VAP diagnosis and prevention: Sam-
pling of the oropharyngeal microbiota around day three to
five of mechanical ventilation could be indicative of VAP
occurring 2–4 days later. Of note, in 50% of patients with
occurrence of a single Enterobacteriaceae no VAP was
diagosed over the clinical course. Therefore this occur-
rence alone is not sufficiently predictive. Co-markers
(such as decreased alpha-diversity) could play an add-
itional role. Such markers need to be identified in a more
extensive study.
From a preventive perspective, our findings could be
interpreted in such a way that efforts to impede Entero-
bacteriaceae accessing the oropharynx should presumably
start immediately after intubation. We think that this find-
ing is generalizable to other settings, as a similar – mono-
clonal - colonization of Enterobacteriaceae in the airways
of ventilated patients has been reported before [30]. De-
creased alpha diversity in lower and upper respiratory
tract samples in ventilated compared to healthy subjects
has also been demonstrated before [24]. Moreover, a de-
crease in longitudinal alpha diversity in VAP patients ver-
sus ventilated controls has been shown before in tracheal
aspirates [23, 31, 32]. Therefore, our data expand this find-
ing to the oropharynx, an anatomical region that is prob-
ably key in the natural history of VAP development [4, 5].
Our results support the findings of a recent study in which
reduced microbial diversity in mechanically ventilated pa-
tients was associated with mortality and was suggested to
be a biomarker of prognostic value [33].
Our findings should be confirmed in a more extensive
study and be compared to data from other critically ill
or previously ventilated patients. In the meantime we
think that our findings should be considered when plan-
ning further studies of predictive diagnostic approaches
or preventive strategies.
Conclusions
In patients who develop enterobacterial VAP the causa-
tive pathogen appears to gain access to the oropharynx
early after starting ventilation and outgrow the com-
mensal members of the microbiome. Whether a specific
pattern of the oropharyngeal microbiome on day three
to five of mechanical ventilation may predict VAP en-
terobacterial VAP has to be evaluated in further studies.
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